Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03155984
Other study ID # UW15-384
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2013
Est. completion date December 1, 2017

Study information

Verified date May 2018
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure. The optimal timing of commencing antiviral therapy and the interval of clinical monitoring is uncertain. 25% of the Hong Kong population has prior HBV exposure. The investigators plan monitor this cohort of patients and determine (1) the optimal time point for starting antiviral therapy based on the progression of HBV reactivation, and (2) the optimal interval of clinical monitoring.


Description:

The use of immunosuppressive cytotoxic therapy in patients with chronic hepatitis B virus (HBV) infection is known to be associated with potentially fatal HBV reactivation. Prophylactic nucleoside analogue therapy has been shown to reduce the rates of HBV reactivation in hepatitis B surface antigen (HBsAg)-positive subjects, and is now recommended in current treatment guidelines.

Patients who are negative for HBsAg and anti-HBsAg antibody (anti-HBs) may be naïve to HBV. Nonetheless in HBV-endemic regions, such patients might have been infected with HBV and achieved HBsAg seroclearance. Prior HBV exposure is evidenced by the presence of positive antibody to the hepatitis B core antigen (anti-HBc). Hence although a HBsAg-negative, anti-HBc positive state may represent resolved HBV infection, it could also represent occult HBV infection with HBV persisting at low replicative levels following HBsAg seroclearance. Reactivation of HBV is then possible.

Rituximab, ofanumumab and obinutuzumab are chimeric monoclonal antibodies against the B-cell surface antigen CD20, and are used extensively in B-cell lymphoid malignancies and many non-malignant immune-mediated diseases in the fields of rheumatology, dermatology, neurology and nephrology.Previous retrospective and prospective studies have found the rates of HBV reactivation in HBsAg-negative, anti-HBc positive individuals who undergo anti-CD20 antibody containing chemotherapy to vary between 8.9 and 23.8%. This variation can be partially explained by the use of different definitions of HBV reactivation, including a combination of biochemical hepatitis, HBsAg seroreversion, or HBV DNA levels over a certain threshold. Another important factor was the lack of regular monitoring following commencement of anti-CD20 antibodies. In view of these discrepancies, our research team conducted a prospective study in which HBsAg-negative, anti-HBc positive lymphoma patients were monitored at 4-week intervals for up to 2 years following commencement of rituximab. Using a detectable serum HBV DNA level as the definition of HBV reactivation, the 2-year cumulative reactivation rate was 41.5%. Anti-HBs negativity was significantly associated with a higher risk of HBV reactivation.

Despite previous accurate description of the rate of HBV reactivation, many clinical questions remain :

1. Which is the better strategy for HBsAg-negative, anti-HBc positive patients receiving anti-CD20 antibodies - prophylactic antiviral therapy for all patients, or regular clinical monitoring and prescription of antiviral therapy when needed? Although prophylactic antiviral therapy has been proven effective, one needs to consider the high seroprevalence of anti-HBc in the HBV-endemic regions of East Asia that could reach 40%. Based on our two studies of rituximab and hematopoietic stem cell transplantation, the seroprevalence of anti-HBc in Hong Kong was between 26.4 and 27.6%. Universal prescription of antiviral therapy for all HBsAg-negative, anti-HBc positive individuals might not be cost-effective. At the same time, a recent technical review by the American Gastroenterological Association stated that based on current evidence, they "had no comment" on whether routine clinical monitoring could substitute prophylactic antiviral therapy.

2. If routine clinical monitoring were chosen, what is the optimal interval of monitoring? A current recommendation of every 1-3 months was based on expert opinion only. To answer this question, a prospective study is needed to observe the serial changes in HBV DNA levels over time in patients following the development of detectable HBV DNA, with each time epoch assessed for its suitability in monitoring.

3. Are all HBV reactivations clinically relevant? Our previous study only provided the rate of HBV DNA detectability, and did not describe its subsequent clinical progression. Will patients continue to have serial increases in HBV DNA level leading to biochemical hepatitis and/or HBsAg seroreversion, or do HBV DNA levels remain relatively low? A recent study found discrepancies between the rates of HBsAg seroconversion and HBV DNA ≥2,000 IU/mL (10.3% and 17.9% respectively), implying not all patients with HBV DNA detectability proceed to a progressive increase in HBV DNA levels, HBsAg seroreversion or biochemical hepatitis. Serial prospective data on this with respect to the cyclical treatment regimen of anti-CD20 antibodies are lacking.

The investigators propose a prospective observational study to answer these clinical questions and provide a concise management strategy for the large number of patients prescribed anti-CD20 antibodies containing therapy for both malignant and non-malignant diseases


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date December 1, 2017
Est. primary completion date June 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age =18 years.

2. Eastern Cooperative Oncology Group (ECOG) performance score of =2.

3. HBsAg-negative, anti-HBc positive patient receiving anti-CD20 containing chemotherapy with or without antibody to the hepatitis B surface antigen (anti-HBs).

4. Baseline normal serum alanine amiontransferase (ALT) (=30 U/L for men, =19 U/L for women).

Exclusion Criteria:

1. Concomitant liver diseases including chronic hepatitis C and D infection, Wilson's disease, autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.

2. Significant alcohol intake (>30 grams per day).

3. History of prior anti-HBV therapy, hematopoietic stem-cell transplantation, anti-CD20 antibody therapy, anti-CD52 antibody therapy or anti-tumour necrosis factor antibody therapy.

4. Baseline detectable HBV DNA (=10 IU/mL). These patients will be started on prophylactic entecavir.

Study Design


Intervention

Drug:
Anti-CD20 antibody
All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies

Locations

Country Name City State
Hong Kong The University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary HBV Reactivation HBV DNA >= 10 IU/mL From commencement of anti-CD20 antibody therapy for up to 2 years
Secondary HBV-related hepatitis ALT >60 U/L for men; >38 U/L for women; and HBV DNA >2,000 IU/mL From commencement of anti-CD20 antibody therapy for up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A